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REVIEW

Cardiotoxicity from Immune Checkpoint Inhibitors: Myocarditis
Laura Onderko, MD,1 Elizabeth Bennett,2 Sanjeev Francis, MD3
1
Maine Medical Center, Department of Medicine, Portland, ME, 2Bates College, Lewiston, ME, 3Maine Medical Center,
Department of Cardiology, Portland, ME

Importance:

Immune checkpoint inhibitors (ICIs) are a class of immunotherapies that have significant clinical efficacy
in treating many cancer types, but they are also associated with systemic effects, including myocarditis.

Objective:

This review describes potential mechanisms underlying ICI-associated myocarditis; data on
epidemiology, including possible risk factors; diagnostic criteria for ICI-associated myocarditis; and
recommendations for managing ICI-associated myocarditis.

Review:

This paper is a narrative literature review that summarizes existing literature to increase awareness of
ICI-associated cardiotoxicities, including myocarditis.

Findings:

Reported cardiovascular adverse events include myocarditis, cardiomyopathy, arrhythmias, pericarditis,
vasculitis, atherosclerotic cardiovascular events, Takotsubo syndrome, and venous thromboembolism.
Myocarditis is associated with the highest risk of morbidity and mortality.

Conclusions:

With increasing use of ICIs, there is an urgent need for greater awareness and understanding of ICIassociated myocarditis. Clinicians need to recognize the diagnostic criteria and develop current treatment
recommendations for ICI-associated myocarditis given the condition’s variable clinical presentation and
potential fulminant course.

Keywords:

myocarditis, cardiotoxicity, immune checkpoint inhibitors, programmed cell death protein 1, cytotoxic
T-lymphocyte-associated protein 4

I

mmune checkpoint inhibitors (ICIs) represent
a major advance in the field of immunotherapy
and have changed the standard of care for many
cancer types. In 2019, an estimated 44% of patients
with cancer in the United States were eligible for
treatment with ICIs.1 Immune checkpoints are
regulatory pathways that attenuate the immune
response and are upregulated by tumor cells to
evade antitumor attack by immune cells.2 ICIs
target immune checkpoints, programmed cell
death protein 1 (PD-1), and cytotoxic T-lymphocyteassociated protein 4 (CTLA-4) to promote the
antitumor immune response.2 Although ICIs have
led to improved survival of patients with cancer,
they are associated with adverse events that affect
various organ systems.3
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OBJECTIVE
This review focuses on ICI-associated myocarditis,
or inflammation of the myocardium.4 Although
cardiotoxicities are not among the most common
type of immune-related adverse events (irAEs), ICIassociated myocarditis can be fatal.5 As the use of
ICIs becomes more common, greater awareness,
timely diagnosis, and effective management of ICIassociated myocarditis is essential.

REVIEW
This narrative literature review is intended for
cardiology providers, oncology providers, and
primary care providers who may encounter patients
treated with ICI therapies. The literature included
in this review was found via a PubMed search
and selected based on relevance to the topic and
reputation of the journal.
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FINDINGS
Immune checkpoints: CTLA-4 and PD-1
In 2018, James P. Allison and Tasuku Honjo were
awarded the Nobel Prize in Physiology or Medicine
for their seminal work in immune checkpoint
pathways. Two central checkpoints, CTLA-4 and
PD-1, participate in signaling pathways essential
in regulating T-cell activation. These checkpoints
inhibit T-cell activation by distinct but potentially
synergistic mechanisms.6 CTLA-4 is a receptor
protein predominantly expressed on naïve T cells
and constitutively expressed on memory T cells and
T-regulatory cells for suppressive functions.7 CTLA4 increases the activation threshold of T cells, thus
functioning as an essential regulatory pathway in
preventing the development of autoreactive T cells
at the initial stage of T-cell activation. This process
could contribute to autoimmune pathology.8
The PD-1 immune checkpoint pathway involves
the transmembrane protein PD-1 and programmed
death-ligand 1 (PD-L1) and PD-L2.9 Whereas
CTLA-4 expression is confined to T cells, PD-1
receptors are also expressed on B, natural killer,
and myeloid cells.9 PD-1 ligands are expressed on
various antigen-presenting cells.8 Although CTLA4 regulates the early stages of T-cell activation
primarily in the lymph nodes and spleen, the PD-1
pathway also regulates the effector phase in later
stages of the immune response in peripheral
tissues.10 In addition to inhibiting the expansion of
naïve self-reactive T cells and their differentiation
into effector cells, PD-1 restricts self-reactive T-cell
effector function.11
Blocking immune checkpoints in cancer
Tumor cells have greater genetic instability than
normal cells and, therefore, can more easily
acquire mutations that upregulate immune
checkpoints.12 This upregulation by malignant cells
results in reduced immune cell growth factors and
a dampened immune response toward malignant
cells.13,14 This effect enables tumor cells to inhibit
T-cell survival and proliferation, induce resistance
against lysis mediated by CD8+ T cells, and create
a molecular shield to avoid immune attack and
tumor-cell apoptosis.12,13 Development of tumor
cells that resist the immune response and selection
of these clones through immunoediting give rise to
a tumor microenvironment that largely suppresses
antitumor immune activity.8,15
https://knowledgeconnection.mainehealth.org/jmmc/vol4/iss1/12
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ICIs, which are monoclonal antibodies (mAbs),
alter the tumor microenvironment by blocking the
CTLA-4 and PD-1 pathways and activating T cells
against cancer cells.2,15 There are 7 approved ICIs
used for cancer therapy, and additional mAbs
targeting the CTLA-4 and PD-1 pathways are under
preclinical and clinical development.11 Ipilimumab,
an anti-CTLA-4 mAb, was the first approved ICI for
treating metastatic melanoma.13 The remaining 6
ICIs all target the PD-1 pathway. Pembrolizumab,
nivolumab, and cemiplimab are mAbs against
PD-1; avelumab, durvalumab, and atezolizumab
are mAbs against PD-L1 (Table 1).11 Non-smallcell lung cancer, renal cell carcinoma, Hodgkin
lymphoma, and, particularly, metastatic melanoma
are the cancer types with the best responses to
ICIs.1 In some malignancies, such as melanoma,
combination therapy has greater efficacy than
monotherapy with a single ICI agent.16
ICI-associated myocarditis
Although ICIs are effective against many cancers,
their use is associated with immune-related adverse
events. Unfortunately, the T-lymphocyte activation
seen with ICIs is not specific to cancer cells, and
autoimmune-like adverse events are common
and involve various organ systems.17 Reported
cardiovascular adverse events include myocarditis,
cardiomyopathy, arrhythmias, pericarditis, vasculitis,
atherosclerotic cardiovascular events, Takotsubo
syndrome, and venous thromboembolism.18
Myocarditis is the most feared complication given
its high mortality rate.18
The exact mechanism underlying ICI-related
myocarditis remains unclear, and there are several
proposed mechanisms. For example, blocking the
PD-1 and CTLA-4 pathways reduces peripheral
immune tolerance to the heart.19 PD-1 and PDL1 are expressed in cardiomyocytes to protect
against autoreactive lymphocytes in the heart.20
Cytotoxic T-lymphocyte killing of myocardial cells
induces secretion of interferon-γ, upregulating
PD-1 expression on surrounding myocardial cells
to protect against further damage.21 It is thought
that PD-1 mAbs inhibit this upregulation, leading
to activation of T cells that target cardiomyocytes.22
Also, blocking CTLA-4 may result in reduced
T-regulatory cells that constitutively express CTLA4.22 Two studies examining mouse models found
that mice lacking the PD-1 receptor developed a
dilated cardiomyopathy.23,24
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Table 1. ICIs Approved by the Food and Drug Administration
Drug
Ipilimumab

Target
CTLA-4

Pembrolizumab

PD-1

Nivolumab

PD-1

Cemiplimab

PD-1

Avelumab
Durvalumab

PD-L1
PD-L1

Indication
Melanoma
Melanoma, non-small-cell lung cancer, Hodgkin’s lymphoma,
squamous cell carcinoma of head and neck, urothelial carcinoma,
gastric cancer, Merkel cell carcinoma
Melanoma, non-small-cell lung cancer, Hodgkin’s lymphoma,
squamous cell carcinoma of head and neck, urothelial carcinoma,
gastric cancer, Merkel cell carcinoma
Non-small-cell lung cancer, locally advanced basal cell carcinoma,
cutaneous squamous cell carcinoma
Merkel cell carcinoma, urothelial carcinoma, renal cell carcinoma
Non-small-cell lung cancer, small-cell lung cancer

Abbreviations: CTLA-4, cytotoxic T-lymphocyte-associated protein 4; ICI, immune checkpoint inhibitor;
PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1.

Postmortem histological analyses of heart tissue
from patients with myocarditis revealed immune
infiltrates in the heart, specifically T-lymphocyte
infiltration of the myocardium were predominantly
CD8+.25 Histological analysis is a valuable tool
for further elucidating mechanisms of checkpoint
blockade-induced cardiotoxicities. Understanding
the exact mechanism underlying ICI-related
myocarditis will be valuable for clinicians and has
the potential to improve treatment.26
Epidemiology
General irAEs occurred in 60% to 80% of patients
treated with ICIs.18 In 3326 patients who received ICIs,
2.4% experienced cardiovascular irAEs.27 Several
analyses found that 0.02% to 1.14% of patients
treated with ICIs develop myocarditis.28,29 Although
the incidence of myocarditis is low, the mortality
is exceedingly high. ICI-induced myocarditis has
a fatality rate estimated at as high as 50%.18,30,31
Mahmood et al. found 46% of myocarditis cases
resulted in a major adverse cardiovascular event,
which includes cardiovascular death, cardiogenic
shock, or cardiac arrest.29 Overall, more than 80%
of cardiovascular irAEs are severe, and 17% of
ICI-induced deaths are cardiac-related.32 Overall,
both the number and proportion of ICI-associated
myocarditis cases compared to all ICI-associated
irAE cases have increased since 2012.30 The true
incidence of ICI-associated myocarditis is likely
underreported due to the challenge of making
the diagnosis, which may not be recognized until
histological analysis at autopsy.33
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Several risk factors exist for developing ICIassociated cardiotoxicity. Combination therapy
with 2 immune checkpoint inhibitors is consistently
associated with an increased incidence of myocarditis
and a higher fatality rate than monotherapy.30,34,35
Genetic factors may influence the risk of developing
myocarditis, but are still largely unknown.36 A
review of 3326 patients treated with ICIs found 3
clinical factors associated with a higher incidence
of myocarditis: history of acute coronary syndrome,
history of heart failure, and age greater than 80
years.27 A separate study of patients treated with
ICIs found diabetes was more common in patients
who developed myocarditis.29 Further research is
needed to develop a more comprehensive riskprediction model for ICI-associated cardiotoxicities.
Diagnosis
Myocarditis has a wide clinical presentation that
ranges from subclinical disease to mild symptoms
(eg, fatigue, general malaise, weakness,
palpitations, chest pain, dyspnea) to severe
symptoms (eg, ventricular arrhythmias, myocardial
injury, heart failure with hemodynamic compromise,
cardiogenic shock, cardiac arrest).5,13,18 The initial
presentation of ICI-associated myocarditis varies
as well. Fulminant myocarditis is characterized by
hemodynamic or electrophysiological instability,37
and it can initially present with a non-dilated
left ventricle with increased wall thickness and
preserved left ventricular function.38 Myocarditis
must be detected early due to the potential for a
more fulminant course.39
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The median time to myocarditis onset is 17 to 34
days18; however, the timing can be variable. One
study reported a range of ICI-associated myocarditis
onset as wide as 5 to 155 days.34 Another study
reported a case of fulminant myocarditis that
developed over 1 year of treatment without any
previous symptoms.40 Overall, most cases occur
earlier in the treatment course. One study reported
that 76% of ICI-myocarditis cases occurred in the
first 6 weeks of ICI treatment, and 64% of patients
received 1 or 2 doses of an ICI before myocarditis
onset.34 Interestingly, the onset of cardiotoxicity
tends to be earlier in patients treated with ICI
combination therapy.5
Concurrent irAEs occur in approximately 50% of
patients with ICI-associated myocarditis.41 Myositis
and myasthenia gravis are the most common,34
possibly due to shared antigens in cardiac and
skeletal muscle.32,42 Diagnosing ICI-associated
myocarditis in patients treated with concurrent
or previous chemotherapy or radiation therapy
requires even greater scrutiny. Because other
cancer therapies (eg, anthracyclines) can also
cause cardiotoxicities,39 it can be challenging to
distinguish which therapy causes the cardiotoxicity.
There is no single test for myocarditis, and the
diagnosis relies on integrating findings from
physical examination, history, electrocardiogram
(ECG), biomarkers, echocardiography, cardiac
magnetic resonance (CMR) imaging, and possibly
endomyocardial biopsy.18
One paper recommended performing a baseline
ECG before each ICI dose and again when the
patient develops cardiac symptoms.37 However,
this recommendation has not been prospectively
validated as a cost-effective strategy. ECG
abnormalities found in patients with ICI-associated
myocarditis include ST-segment changes and
arrhythmias, the latter associated with a poor
prognosis.38 ST-elevation mimicking myocardial
infarction can indicate fulminant myocarditis.37
Although ECG is highly sensitive in detecting cardiac
irAEs and is commonly abnormal for myocarditis,
ECG lacks enough specificity to be the only test for
diagnosing myocarditis.18,37
ICI-associated myocarditis is typically characterized
by an elevated troponin, which reflects myocardial
injury.38 Troponin is generally regarded the most
sensitive biomarker for myocarditis,5 although it
https://knowledgeconnection.mainehealth.org/jmmc/vol4/iss1/12
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may be initially normal in some cases.43 An elevated
troponin can also indicate myocardial injury from other
mechanisms, such as pre-existing cardiovascular
disease, cancer progression, or acute coronary
syndrome.44 Additional cardiac biomarkers should
also be assessed for abnormalities, including total
creatine kinase, creatine kinase-myocardial band,
and N-terminal pro-brain natriuretic peptide.40
Echocardiography is most often the initial imaging
test in cases of suspected myocarditis.45 Findings
that support myocarditis include abnormalities of
left or right ventricular systolic function, new-onset
diffuse or segmental wall motion abnormalities,
changes in the size of cardiac chambers,
pericardial effusion, and diastolic dysfunction with
preserved ejection fraction.37,45 Myocarditis may
resemble dilated, hypertrophic, and restrictive
cardiomyopathy on echocardiography.45 As with
other diagnostic tests, echocardiography alone
cannot make the diagnosis as it lacks specificity,
and patients with severe myocarditis can have a
normal echocardiogram.18
Because many patients with ICI myocarditis will
present with chest pain, biomarker and/or ECG
evidence of myocardial injury is important to
exclude non-ICI etiologies, such as coronary artery
disease. The threshold for pursuing coronary
angiography will depend on the clinical scenario
and patient-specific factors. This threshold should
be considered given the prevalence of cardiac risk
factors and established cardiovascular disease in
many patients with cancer.42
CMR imaging is the gold standard for the imaging
diagnosis of non-ICI-associated myocarditis, relying
on the presence of imaging markers of myocardial
edema and myocardial injury (ie, late gadolinium
enhancement).39 Importantly, CMR diagnostic
criteria have been validated for non-ICI myocarditis,
and criteria specific for ICI-associated myocarditis
are lacking. Zhang et al. reported that 58% of 77
patients with ICI-associated myocarditis had a
normal left ventricular ejection fraction, and only
52% of patients had late gadolinium enhancement.46
Using the established diagnostic criteria for nonICI myocarditis (referred to as the Lake Louise
Criteria), less than 50% of patients with confirmed
ICI myocarditis who presented with a preserved
ejection fraction had neither late gadolinium
enhancement nor evidence of myocardial edema
on standard imaging.47 These results caution
4
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against an overreliance on non-ICI-myocarditis
criteria. Recently, Thavendiranathan et al. reported
using the CMR technique to characterize tissue
with quantitative parametric mapping (also known
as T1 and T2 mapping).48 Using these parameters
led to improved sensitivity and prognostic value
in this retrospective registry.46 Further studies are
needed to validate these findings.
Endomyocardial biopsy is still the gold standard for
non-ICI myocarditis, though routine use of biopsy
is uncommon.37 In the case of ICI-associated
myocarditis, endomyocardial biopsy is important,
particularly when the diagnosis is uncertain based
on clinical and imaging characteristics. An early
and accurate diagnosis is critical to ensure that
treatment strategies begin quickly. Moreover,
rechallenging patients with an ICI after myocarditis
develops is typically avoided due to the risk of
recurrent myocarditis.42 As such, an accurate
diagnosis of ICI myocarditis is key when the stakes
are so high.
Overall, the diagnosis of ICI-associated myocarditis
remains challenging and requires a combination
of clinical, ECG, laboratory, imaging, and possibly
histologic data (Table 2). Increased awareness of
ICI-associated myocarditis is an important step
toward early detection and treatment. In patients
who present with cardiovascular symptoms while
on ICIs, there should be a low threshold to pursue
further testing and involve cardiovascular specialists
given the high risk of morbidity and mortality.
Management
Early diagnosis of ICI-associated myocarditis is
critical to initiate management, which involves
discontinuing ICI therapy and immediately
administering corticosteroids.20,39 For most grade
1 non-cardiac irEAs, continuing ICI treatment with
careful monitoring is standard care; however, for
all grades of cardiac irAEs, ICI treatment must
be discontinued due to the more severe course.49
Standard corticosteroid treatment involves systemic
prednisone or methylprednisolone at 1 to 2 mg/kg/
day for 4 to 6 weeks.18,39,49 Mahmood et al. found
a higher initial dose of methylprednisolone was
associated with fewer major adverse cardiac events
and a lower final serum troponin level.29 Troponin
levels should be monitored serially to assess the
patient’s response to the steroids.42 Myocarditis
may worsen despite an initial improvement
from corticosteroid therapy.42 If the patient is
Published by MaineHealth Knowledge Connection, 2022

unresponsive to initial corticosteroids or their
condition worsens, higher doses of corticosteroids
can be tried (1 g methylprednisolone/day).3 If there
is a limited response to steroids, then additional
immunosuppressants should be considered, such
as abatacept,26 alemtuzumab,50 mycophenolate
mofetil, and infliximab.39,49 Infliximab should be used
cautiously because of the risk of worsening heart
failure; a lower dose of 5 mg/kg instead of 10 mg/kg
is advised for patients with acute decompensated
heart failure.42 High-dose infliximab is also
contraindicated in patients with left ventricular
dysfunction.43 In terms of other treatments, reports
have suggested using antithymocyte globulin
and tacrolimus.32 32 Intravenous immunoglobulin,
plasmapheresis, and immunoadsorption therapy
may also be considered in steroid-refractory
cases.19,42 There is limited consensus and lack of a
large evidence base to guide treatment after starting
corticosteroids. Consultation with dedicated cardiooncologists is recommended if available.

CONCLUSIONS

This review highlights that ICI-associated
myocarditis remains a challenging diagnosis due to
its variable clinical presentation and requires a high
index of suspicion in the early phase.
Early diagnosis is critical given the potential fulminant
course that is associated with a high mortality rate.
There is a need for more comprehensive diagnostic
criteria and for effective screening strategies. Also,
future research on risk factors is essential to help
generate a more robust risk-prediction tool. The
true incidence of ICI-associated myocarditis is
likely higher than described in the literature and
highlights the need for additional epidemiological
studies. In terms of treatment, there is a need
for research on optimal treatment pathways,
such as randomized controlled trials examining
corticosteroid dosages/duration or efficacy of
various additional immunosuppressants in steroidrefractory cases. As use of immune checkpoint
inhibitors increases, a better understanding of ICIassociated cardiotoxicities is paramount.
Conflicts of Interest: None
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